{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:58:06Z","timestamp":1783033086361,"version":"3.54.6"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p>\n                    This study compares the efficacy, safety, and tolerability of a partial dopamine agonist, aripiprazole, with placebo in the treatment of patients with bipolar I disorder experiencing an acute manic or mixed episode. In total, 272 hospitalized patients were randomized to aripiprazole 30mg\/day or placebo in this 3-week, double-blind, placebo-controlled trial. Dosing could be reduced to 15mg\/day for tolerability and, subsequently, increased to 30mg\/day based on clinical response. Primary efficacy measure was mean change from baseline to endpoint in Young Mania Rating Scale (YMRS) total score; response was defined as 50% decrease from baseline YMRS score. Aripiprazole-treated patients demonstrated significantly greater improvement from baseline to endpoint in mean YMRS total scores compared with placebo-treated patients as early as Day 4 and sustained through Week 3. A significantly higher response rate was observed in aripiprazole-treated patients (53% vs. 32% at endpoint). Aripiprazole produced significantly greater improvements from baseline on other efficacy assessments compared with placebo, including Clinical Global Impression \u2013 Bipolar Version Severity and Improvement scores. The 30mg\/day dose was maintained by 85% of aripiprazole-treated patients. Incidence of discontinuations due to adverse events was similar for aripiprazole (8.8%) and placebo (7.5%). Aripiprazole treatment resulted in no significant difference from placebo in change in mean body weight and was not associated with elevated serum prolactin or QT\n                    <jats:sub>c<\/jats:sub>\n                    prolongation. In conclusion, aripiprazole demonstrated superior efficacy to placebo in the treatment of patients with bipolar I disorder presenting with acute manic or mixed episodes, and exhibited a favourable safety and tolerability profile.\n                  <\/jats:p>","DOI":"10.1177\/0269881106059693","type":"journal-article","created":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T21:23:19Z","timestamp":1139952199000},"page":"536-546","source":"Crossref","is-referenced-by-count":195,"title":["Aripiprazole in the treatment of acute manic or mixed episodes in patients                 with bipolar I disorder: a 3-week placebo-controlled study"],"prefix":"10.1177","volume":"20","author":[{"given":"Gary","family":"Sachs","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Stock","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Company, Wallingford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mcquade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Carson","sequence":"additional","affiliation":[{"name":"Otsuka America Pharmaceutical Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neveen","family":"Abou-Gharbia","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Impellizzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kaplita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Rollin","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Company, Wallingford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Co. Ltd, Chiyoda-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2006,7,1]]},"reference":[{"key":"atypb1","first-page":"22","volume":"62","author":"Allison D B","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"},{"issue":"23","key":"atypb3","first-page":"13","volume":"62","author":"Aronne L J","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(94)90064-7"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015040-00004"},{"issue":"4","key":"atypb7","volume":"13","author":"Bourin M","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.033175"},{"issue":"14","key":"atypb9","first-page":"34","volume":"62","author":"Calabrese J R","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199702001-00004"},{"issue":"1","key":"atypb11","first-page":"S185","volume":"5","author":"Cornblatt B","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00159-5"},{"issue":"122","key":"atypb13","volume":"13","author":"Graves E J","year":"1995","journal-title":"Vital Health Stat"},{"key":"atypb14","doi-asserted-by":"crossref","unstructured":"Guy W                  (ed.) (1976) ECDEU Assessment Manual for Psychopharmacology                     Revised Edition. Publication ADM 76\u2013338.                      US Department of Health, Education, and Welfare, Rockville, MD                 , pp. 217\u2013222","DOI":"10.1037\/e591322011-001"},{"issue":"3","key":"atypb15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00023210-199810030-00005","volume":"10","author":"Hamner B M","year":"1998","journal-title":"CNS Drugs"},{"issue":"8","key":"atypb16","first-page":"15","volume":"64","author":"Hirschfeld R M","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01532-7"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0903"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003651"},{"key":"atypb20","volume-title":"The Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay S R","year":"1986"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(00)00177-4"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1017\/S0924270800035547"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00961-6"},{"issue":"1","key":"atypb26","first-page":"S176","volume":"5","author":"McQuade R D","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00050-1"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0910"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0410"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00334-8"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.12.1147"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1210"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881106059693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881106059693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:09:54Z","timestamp":1777507794000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881106059693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1177\/0269881106059693"],"URL":"https:\/\/doi.org\/10.1177\/0269881106059693","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}